PCSK9 inhibition in heart failure ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen A new ASO PCSK9 inhibitor: The Etesian study siRNA-mediated lowering of Lp(a) by SLN360 CLEAR OUTCOMES: Topline data show bempedoic acid reduces cardiovascular events

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

What’s new on the horizon for lipoprotein(a) therapies?

Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

VIDEO: New insights from ODYSSEY OUTCOMES VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) A new ASO PCSK9 inhibitor: The Etesian study CLEAR OUTCOMES: Topline data show bempedoic acid reduces cardiovascular events New clues to PCSK9-LDL receptor degradation mechanism How do clinicians translate intensive LDL-C lowering to their practice? Why should clinical practice move to an intensive LDL-C lowering approach?

Most viewed

VIDEO: New insights from ODYSSEY OUTCOMES

Hot Topics

17th Virtual Closed Scientific Expert Meeting of the Editorial Board

What's new in lipoprotein(a) therapeutics?
Dr Michael Koren overviews the latest data with the siRNA olpasiran, including the OCEAN(a) trial.

Watch now

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

View all presentations from the 17th Closed Scientific Expert Meeting »

From the Editors

Lipoprotein(a) and atrial fibrillation – Is there a link?

John chapman & Henry Ginsberg Profs. John Chapman and Henry Ginsberg discuss new data implicating Lp(a) as a potential causal mediator of atrial fibrillation.